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INTRODUCTION
Philadelphia chromosome (Ph) is the genetic hallmark of chronic myeloid leukemia (CML) and is caused by reciprocal translocation between chromosomes 9 and 22 resulting in formation of BCR-ABL fusion protein. The BCR-ABL oncoprotein can vary in size depending on the breakpoint location within the BCR gene. The position of the breakpoint in ABL is consistent at the 5' end of exon a2, while the breakpoint location in BCR can occur at one of three positions namely major-bcr (M-bcr), minor-bcr (m-bcr) and micro-bcr (μ-bcr). [1] The most commonly associated breakpoint with CML is M-bcr in either exon 13 or exon 14, producing splice variant b2a2 or b3a2 respectively. Both splice variants encode for oncoprotein p210 BCR-ABL. [1, 2] If the breakpoint occurs at m-bcr in exon e1, p190 BCR-ABL form of the oncoprotein is encoded. The fusion transcripts of CML can be separated based on the differences in the site of breakpoint and types of BCR-ABL transcripts i.e., b3a2 is larger by 75 base pairs or 25 amino acids than b2a2 and presence of a different amino acids in these i.e., lysine in b3a2 and glutamic acid in b2a2. [3] Regarding the distribution of major transcripts b3a2 and b2a2, there are mixed opinions as per literature. Few studies have reported the higher frequency of b3a2 transcript than b2a2. [4] [5] [6] [7] [8] [9] Other studies have shown more prevalence of b2a2 than b3a2 transcript. [10] [11] [12] How to cite this article: Sazawal S, Chhikara S, Singh K, Chaubey R, Mahapatra M, Seth T, et al. 
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Influence of these transcripts on hematological parameters is also variable as per various studies. [7, 10, 13] Impact of the fusion transcripts on the treatment outcome and prognosis of Imatinib treated CML patients is still a matter of debate. Different studies from the West have shown contradictory results regarding the treatment response among the b3a2 and b2a2 fusion transcripts. [10, 11, [14] [15] [16] [17] In Indian population, there is paucity of data regarding distribution of various CML fusion transcripts, clinico-hematological parameters and treatment response. In view of this, we conducted this study in a study group of 400 CML-CP patients to look for the distribution of common fusion transcripts i.e. b3a2 and b2a2, their clinico-hematological profile and impact on treatment outcome in newly diagnosed CML patients treated with Imatinib. These patients consisted of 260 males and 140 females with median age 37 years. All these patients were started on oral Imatinib 400-800 mg/day (Novartis, Bale, Switzerland). The study was approved by the Institutional Ethics Committee and written informed consent was obtained from all the participants. CML patients in accelerated phase (AP) or blast crisis (BC), chronic myelomonocytic leukemia (CMML) patients and other myeloproliferative disorder patients were excluded from the study.
MATERIALS AND METHODS
T h i s w a s a r e t r o s p e c t i v e s t u d
Baseline characteristics of the patients including age, gender, hemoglobin, total leucocyte count (TLC) and platelet count were recorded. Real-time quantitative PCR (RQ-PCR) was performed on peripheral blood every 3-6 months to look for molecular response which was defined as major molecular response (MMR) if the BCR-ABL/ABL ratio was <0.10% on the International Scale [IS]. [18] For performing RT-PCR and RQ-PCR, 10 ml peripheral venous blood was collected in 1.6% EDTA container and RNA was isolated using the commercially available kit (Qaigen miniamp). The concentration of RNA was measured spectrophotometrically using NANODROP (ND-1000 spectrophotometer). cDNA was then synthesized using MuLV reverse transcriptase and other reaction components (Thermo CAT# AB-1453/A), according to the protocol provided by the manufacturer. cDNA quality was checked by amplification of β2 microglobulin gene. cDNA synthesis was followed by multiplex-PCR to detect the fusion transcript. Expected band size was 472 bp for b3a2 and 397 bp for b2a2 transcript [ Figure 1 ].
To assess molecular responses using RQ-PCR, BCR-ABL and internal control transcript levels were quantified using real-time polymerase chain reaction (PCR) Taqman assay. [19] In this assay, ABL gene transcript levels were measured as a reference in each patient sample. To quantify the copy number of the reference ABL and target BCR-ABL fusion gene transcripts in patient samples, standard curves were generated based on the known concentration of plasmid serial dilutions of both ABL and BCR-ABL genes. Using the cycle threshold (Ct) value obtained from real-time PCR, the copy numbers of target and reference genes were calculated in patient samples from the respective standard curves and BCR-ABL transcript levels were expressed as BCR-ABL transcript copies/ABL transcript copies. The calculation of the ratio of specific fusion gene transcript copy number to endogenous ABL copy number provided a normalized quantification of the specific fusion gene independent of the lymphocyte count in each assayed sample and also compensated for variations in the quality of the RNA and for differences in efficiency of reverse transcriptase reactions [ Figure 2 ].
Statistical analysis
The Chisquare method was applied for comparing obtained BCR-ABL1 variants of the CML patients by gender. Statistical analysis was performed using the STATA 11 (College Station, TX, USA). Chisquare analysis and Fisher exact test were carried out to compare the difference of frequencies between groups of patients. P value of <0.05 was considered statistically significant.
RESULTS
The clinico-pathological parameters of the patients are summarized in Table 1 . Of the 400 CML-CP patients, 260 (65%) were males and 140 (35%) were females (median age 37, range 12-70 years). The overall frequency of b3a2 transcript was observed in 288 (72%) followed by b2a2 in 104 (26%) and hybrid fusion transcript (b3a2 + b2a2) was seen in 8 (2%) cases. Among hematological parameters, 96 (33.3%) b3a2 patients had Hb >10 g/dl and 192 (66.7%) had Hb ≤10 g/dl. For b2a2 patients, 36 (34.6%) patients had Hb >10 g/dl and 68 (65.4%) had Hb ≤10 g/dl. 260 (90.2%) b3a2 patients had TLC >11 × 10 9 /l and 28 (9.8%) had TLC ≤11 × 10 9 /l. For b2a2 patients, 100 (96.1%) patients had TLC >11 × 10 9 /l and 4 (3.9%) had TLC ≤11 × 10 9 /l. 268 (93%) b3a2 patients had platelet count >100 × 10 9 /l and 20 (7%) had platelet count ≤ 100 × 10 9 /l. For b2a2 patients, 92 (88.4%) patients had platelet count >100 × 10 9 /l and 12 (11.6%) had platelet count ≤100 × 10 9 /l. Despite being the commonest leukemia in Asia, very few studies from India have documented the frequency of BCR-ABL fusion transcripts. [7, 10, 20] Furthermore, disease phenotype of patients and treatment response of CML-CP patients varies in different fusion transcripts and sparsely documented especially in Indian population. [10] [11] [12] [13] [14] [15] In our study, b3a2 was most common fusion transcript; seen in 288 (72%) patients, followed by b2a2 seen in 104 (26%) patients. b3a2+b2a2 co-transcript was observed in 8 (2%) patients. Our results are comparable to study by Iqbal et al., Anand et al., Yaghmaie and Goh et al. in Saudi Arabian, North Indian, Iranian and Korean population respectively. [5, 6, 8, 21] Contrary to this, frequency of b2a2 was higher than b3a2 in Western population. [11, 12, 17] Among the hematological parameters, 33.3% b3a2 patients had Hb >10 g/dl and 66.7% had Hb ≤10 g/dl. In b2a2 patients, 34.6% patients had Hb >10 g/dl and 65.4% had Hb ≤10 g/dl (P = 0.866). Our results are comparable to the study by Perego et al. and deLemos et al. [17, 22] When we compared the association of fusion transcripts with TLC and platelet count, 90.2% b3a2 patients had TLC >11 × 10 9 /l and 9.8% had TLC ≤11 × 10 9 /l. In b2a2 patients, 96.1% patients had TLC >11 × 10 9 /l and 3.9% had TLC ≤11 × 10 9 /l (P = 0.245). This finding was in line with Perego et al. and deLemos et al. [17, 22] However, Mondal et al. and Martinez Mancilla et al. reported the association of raised TLC with b2a2 transcript as compared to b3a2 transcript. [7, 23] Among patients with b3a2 fusion transcript, 93% cases had platelet count >100 × 10 9 /l and 7% cases had platelet count ≤100 × 10 9 /l. Among b2a2 patients, 88.4%patients had platelet count >100 × 10 9 /l and 11.6% had platelet count ≤100 × 10 9 /l (P = 0.374).Our results are in line with Shepherd et al. [13] However, few studies have shown that patients with the b3a2transcript have a higher platelet count than patients with the b2a2transcript. [17, 22] There are mixed opinions regarding the molecular response to Imatinib in b3a2 and b2a2 fusion transcripts. In our study we found that better major molecular response (MMR) was attained in b3a2 patients (68.7%) as compared to b2a2 patients (42.3%) (P = 0.001). Our findings are in line with study by Hanfstein et [11, [14] [15] [16] Italian GIMEMA working party investigated 559 patients on Gleevec treatment and found a significantly shorter time to MMR in the b3a2 group. [15] Vega-Ruiz et al. analyzed 480 patients and found significantly lower BCR-ABL1 levels in the b3a2 group at three, six, and nine months. [11] Lucas et al. investigated 78 patients and showed a faster achievement of CCyR in the b3a2 group, which was explained by a higher kinase activity of b3a2 BCR-ABL1.
Better response rates for b2a2 have been reported in Western patients. [17] Few studies showed no difference in MMR among b3a2 and b2a2 transcripts. [10, 24] In conclusion, the frequency of b3a2 transcript was more as compared to b2a2 transcript. MMR was significantly higher in patients with b3a2 transcript as compared to patients with b2a2.
